Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Weill Cornell Medicine TREM2 compound 4i
- Development stage
- Unknown
- Lead developer
- Weill Cornell Medicine
01
Overview
Weill Cornell Medicine TREM2 compound 4i: sourced facts only. name: "Pre-liminary optimization yielded 4i, which maintained TREM2 engagement with improved selectivity over TREM1 and no cytotoxicity." [PMID:41240472]; target: "Pre-liminary optimization yielded 4i, which maintained TREM2 engagement with improved selectivity over TREM1 and no cytotoxicity." [PMID:41240472]; developer: "Department of Radiology, Molecular Imaging Innovations Institute (MI3), Weill Cornell Medicine, New York, NY, 10065, USA." [PMID:41240472]
02
Targets
TREM2 (Triggering receptor expressed on myeloid cells 2)
Beyond the preview
Go deeper on Weill Cornell Medicine TREM2 compound 4i.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Weill Cornell Medicine TREM2 compound 4i.